Pioneering cellular medicines for women’s health

We’re developing off-the-shelf cell therapies for high-impact women’s diseases, with lead programs in ovarian cancer, triple negative breast cancer and endometriosis.

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.

Learn more about us

Some of our partners

Latest news

Ovarian cancer: Biotech company Cartherics to start human trials of new drug

By Christine Filippis / February 12, 2024
There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when...
Read More

Positive pre-IND meeting with US FDA for new ovarian cancer cell therapy

By Christine Filippis / February 1, 2024
Melbourne, Australia, 1 February 2024 –  Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the...
Read More

Cartherics to present at Australia Biologics Festival 2024

By Christine Filippis / January 23, 2024
Cartherics is pleased to announce that Dr Ian Nisbet, Chief Operating Officer, will be presenting at Australia Biologics 2024 at...
Read More